Terms: = Lung cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
167 results:
1. Targeting the CXCL12/cxcr4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract] [Full Text] [Related]
2. CD34
Perrone C; Bozzano F; Dal Bello MG; Del Zotto G; Antonini F; Munari E; Maggi E; Moretta F; Farshchi AH; Pariscenti G; Tagliamento M; Genova C; Moretta L; De Maria A
Front Immunol; 2024; 15():1332781. PubMed ID: 38390333
[TBL] [Abstract] [Full Text] [Related]
3. cxcr4-directed PET/CT with [
Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
[TBL] [Abstract] [Full Text] [Related]
4. [Exploration of the Perturbation of PKIG in lung Squamous Cell Carcinoma and the Role in Tumor Microenvironment Based on Bioinformatics Method].
Liu Q; Li H; Li B; Ren M; Li Z; Chen Y; Zheng Z; Meng Y; Feng H
Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):523-537. PubMed ID: 37653016
[TBL] [Abstract] [Full Text] [Related]
5. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
6. cxcr4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/cxcr4 signaling axis in preclinical breast cancer model.
Gupta N; Mohan CD; Shanmugam MK; Jung YY; Chinnathambi A; Alharbi SA; Ashrafizadeh M; Mahale M; Bender A; Kumar AP; Putti TC; Rangappa KS; Zhang X; Ahn KS; Sethi G
Environ Res; 2023 Sep; 232():116335. PubMed ID: 37290620
[TBL] [Abstract] [Full Text] [Related]
7. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept.
Khaparkhuntikar K; Maji I; Gupta SK; Mahajan S; Aalhate M; Sriram A; Gupta U; Guru SK; Kulkarni P; Singh PK
J Biomol Struct Dyn; 2024; 42(3):1469-1484. PubMed ID: 37272883
[TBL] [Abstract] [Full Text] [Related]
8. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Alsadhan A; Chen J; Gaglione EM; Underbayev C; Tuma PL; Tian X; Freeman LA; Baskar S; Nierman P; Soto S; Itsara A; Ahn IE; Sun C; Bibikova E; Hartmann TN; Mhibik M; Wiestner A
Clin Cancer Res; 2023 Sep; 29(18):3612-3621. PubMed ID: 37227160
[TBL] [Abstract] [Full Text] [Related]
9. A Multiple Targeting Nanoprobe for Identifying cancer Metastatic Sites Based on Detection of Various mRNAs in Circulating Tumor Cells.
Han D; Ren XH; Liao XR; He XY; Guo T; Chen XS; Pang X; Cheng SX
Nano Lett; 2023 May; 23(9):3678-3686. PubMed ID: 37052638
[TBL] [Abstract] [Full Text] [Related]
10. One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or cxcr4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T; Borchert S; Wessolly M; Mathilakathu A; Mairinger E; Kollmeier J; Mairinger T; Hegedus B; Greimelmaier K; Wohlschlaeger J; Herrmann K; Mairinger FD
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047331
[TBL] [Abstract] [Full Text] [Related]
11. DHA- and EPA-Enriched Phosphatidylcholine Suppress Human lung Carcinoma 95D Cells Metastasis via Activating the Peroxisome Proliferator-Activated Receptor γ.
Yin H; Liu Y; Yue H; Tian Y; Dong P; Xue C; Zhao YT; Zhao Z; Wang J
Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364935
[TBL] [Abstract] [Full Text] [Related]
12. Mechanisms of Biochanin A Alleviating PM2.5 Organic Extracts-Induced EMT of A549 Cells through the PI3K/Akt Pathway.
Wang Y; Zhang Y; Li Y; Kou X; Xue Z
J Nat Prod; 2022 Oct; 85(10):2290-2301. PubMed ID: 36181478
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive analysis of CXCR family members in lung adenocarcinoma with prognostic values.
Hu LT; Deng WJ; Chu ZS; Sun L; Zhang CB; Lu SZ; Weng JR; Ren QS; Dong XY; Li WD; Li XB; Du YT; Li Y; Wang WQ
BMC Pulm Med; 2022 Jun; 22(1):259. PubMed ID: 35768814
[TBL] [Abstract] [Full Text] [Related]
14. cxcr4-targeted theranostics in oncology.
Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in cancer Therapy.
De Sanctis JB; Charris J; Blanco Z; Ramírez H; Martínez GP; Mijares MR
Anticancer Agents Med Chem; 2023; 23(10):1122-1144. PubMed ID: 35598250
[TBL] [Abstract] [Full Text] [Related]
16. Estrogen receptor beta promotes lung cancer invasion via increasing cxcr4 expression.
Liu S; Hu C; Li M; An J; Zhou W; Guo J; Xiao Y
Cell Death Dis; 2022 Jan; 13(1):70. PubMed ID: 35064116
[TBL] [Abstract] [Full Text] [Related]
17. "Attractive/adhesion force" dual-regulatory nanogels capable of cxcr4 antagonism and autophagy inhibition for the treatment of metastatic breast cancer.
Dong J; Zhu C; Zhang F; Zhou Z; Sun M
J Control Release; 2022 Jan; 341():892-903. PubMed ID: 34953982
[TBL] [Abstract] [Full Text] [Related]
18. The Embryonic Key Pluripotent Factor NANOG Mediates Glioblastoma Cell Migration via the SDF1/cxcr4 Pathway.
Sánchez-Sánchez AV; García-España A; Sánchez-Gómez P; Font-de-Mora J; Merino M; Mullor JL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638956
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of the Significance of Immune Cell Infiltration and Prognosis of Non-Small-Cell lung cancer by Bioinformatics.
Sun H; Sui B; Li Y; Yan J; Cao M; Zhang L; Liu S
J Healthc Eng; 2021; 2021():3284186. PubMed ID: 34603645
[TBL] [Abstract] [Full Text] [Related]
20. [Mesenchymal Stem Cells Cultured in 3D System Inhibit Non-small Cell lung cancer Cells Through p38 MAPK and cxcr4/AKT Pathways by IL-24 Regulating].
Suo F; Pan M; Li Y; Yan Q; Hu H; Hou L
Mol Biol (Mosk); 2021; 55(4):643-659. PubMed ID: 34432782
[TBL] [Abstract] [Full Text] [Related]
[Next]
